TIL Therapy Turns a Patient’s Own Immune Cells on Melanoma

What if the immune cells already sitting inside your tumour could be trained up and sent back in far greater numbers? That is the idea behind TIL therapy.

It is a personalized form of cellular immunotherapy. Doctors collect immune cells from a tumour, grow them in a laboratory, and return them to you so your body can better recognize and attack the cancer. It is used mainly for certain adults with advanced melanoma after other systemic treatments have stopped working, or are no longer suitable for you.

TIL Therapy Explained: An Overview

TIL therapy, short for tumor-infiltrating lymphocyte therapy, is a type of adoptive cell therapy. It uses a person’s own immune cells, taken from a surgically removed tumor, to support the immune system’s ability to find and attack cancer cells. The best-established current use is for adults with advanced or metastatic melanoma that cannot be removed completely with surgery.

Tumor-infiltrating lymphocytes are white blood cells that have entered a tumor naturally. Their presence suggests that the immune system has recognized something abnormal, although the existing response may not be strong enough to control the cancer. In TIL therapy, these cells are collected, selected and expanded outside the body, then infused back in much larger numbers.

This is not the same as standard immunotherapy medicines such as immune checkpoint inhibitors, which work by switching on immune responses your body already has. TIL therapy is individualized because the cells are grown from each patient’s own tumor. It is delivered at experienced cancer centers with cell-therapy, surgical, medical oncology, pathology, pharmacy and intensive supportive-care teams.

How TIL Therapy Works

First, a surgeon removes a tumor sample that is large enough and safely located for cell manufacturing. In a specialized laboratory, lymphocytes are isolated from the sample and grown using immune-signaling proteins. Over several weeks, the laboratory produces a large number of the patient’s TILs for infusion.

Before the cells are returned, the patient receives a short course of lymphodepleting chemotherapy. This temporarily reduces some existing immune cells and can create a more favorable environment for the infused TILs to expand and function. The prepared cells are then given through a vein, similar to a blood-cell infusion.

After infusion, patients usually receive high-dose interleukin-2, an immune-stimulating medicine that helps support the activity of the transferred TILs. This phase requires inpatient monitoring because interleukin-2 and the preceding chemotherapy can cause important, but often manageable, effects on blood pressure, fluid balance, organs and blood counts.

Researchers are still working on how to refine this approach, combine it with other treatments, or use it in other cancers. For now, though, whether you are eligible and how much you might gain depends on your cancer type, the treatments you have already had, your general health and whether a suitable tumour sample can be taken.

Who May Be a Candidate for TIL Therapy?

TIL therapy may be an option for an adult with unresectable or metastatic melanoma that has progressed after treatment with an anti-PD-1 immunotherapy medicine. For melanoma with certain targetable gene changes, prior targeted therapy may also be considered when clinically appropriate. A specialist team reviews the full treatment history rather than relying on one factor alone.

Candidacy also depends on whether a tumor can be safely removed to make the cell product, whether there is enough time for manufacturing, and whether a person can tolerate chemotherapy, hospitalization and interleukin-2. Heart, lung, kidney and liver function, blood counts, infection status, functional ability and other medical conditions are carefully assessed.

TIL therapy is not the right choice for every person with melanoma. Cancer may be growing too quickly to wait for the manufacturing period, the tumor location may make collection unsafe, or health conditions may increase treatment risk. A cancer team can discuss alternatives, which may include systemic medicines, radiation therapy, surgery, symptom-focused care or clinical trials.

If you are thinking about cellular treatment, ask for an individual oncology review. It should look at how far the disease has spread, your molecular test results, how you responded to earlier therapies, what matters most to you, and what practical help you will need while recovering.

The TIL Therapy Timeline: Step by Step

The TIL therapy timeline begins with evaluation and planning. This includes imaging, laboratory tests, heart and lung assessment when needed, review of previous pathology and treatment records, and discussion of possible risks. A surgeon then removes a tumor sample, often through an outpatient or short inpatient procedure depending on its location.

Manufacturing the cell product takes several weeks. During this interval, the oncology team monitors the cancer and may discuss whether any treatment is needed as a bridge. Not every sample ends up producing a usable product. That is one reason we plan carefully and talk openly about what to expect.

Once the product is ready, admission to hospital is generally needed. Lymphodepleting chemotherapy is given first, followed by the TIL infusion and then interleukin-2. The precise schedule varies by protocol and individual health needs, but the intensive treatment phase commonly involves several weeks of inpatient care and monitoring.

After discharge, follow-up includes blood tests, assessment for delayed side effects, rehabilitation as needed and scheduled scans. Follow-up visits are an essential part of treatment, because recovery from low blood counts and fatigue can take time, and the care team needs to assess both cancer response and overall wellbeing.

Benefits, Risks and Recovery After TIL Therapy

The potential benefit of TIL therapy is that it offers a personalized treatment approach for some people whose advanced melanoma has continued to grow despite prior treatment. Some patients experience tumor shrinkage, and some responses can last a long time. However, response cannot be predicted reliably for an individual, and treatment does not guarantee cancer control.

Most side effects arise from lymphodepleting chemotherapy and interleukin-2 rather than from the cell infusion itself. They may include fatigue, fever, chills, nausea, diarrhea, low blood pressure, fluid retention, shortness of breath, reduced blood counts, infection risk and temporary effects on kidney, liver or heart function. The care team monitors patients closely and provides supportive treatment when needed.

Recovery is individual. Blood counts and energy levels often improve gradually after the inpatient phase, but tiredness, reduced appetite and lower stamina may continue for weeks. Patients may need help with daily tasks, transportation and appointments after returning home. The oncology team will advise when work, exercise and travel can be resumed safely.

Contact the treatment team promptly for fever, worsening shortness of breath, chest discomfort, fainting, confusion, severe vomiting or diarrhea, unusual bleeding, new swelling, or any symptom that feels urgent. Any of these can have several causes. After intensive cancer treatment, though, it is far better to be checked early than to wait and see.

How Long Does It Take for TIL Therapy to Start Working?

TIL therapy begins acting biologically after the cells are infused, but it usually takes time to know whether the cancer is responding. Imaging is commonly scheduled weeks to a few months after treatment, with the exact timing determined by the oncology team. Symptoms, examination findings and blood tests can also contribute to the assessment.

A scan soon after treatment may not provide the complete picture. Immune activity and inflammation can occasionally make tumors look temporarily larger or reveal changes that need careful interpretation. For this reason, doctors compare scans over time and consider the person’s symptoms and overall clinical condition.

If cancer symptoms worsen during the manufacturing or recovery period, patients should tell their care team rather than wait for the next planned visit. The team can assess whether the symptoms are related to the cancer, treatment effects, infection or another problem and can recommend appropriate support.

Is TIL Therapy Worth It?

Whether TIL therapy is worth it is a personal and clinical decision. For a person with eligible advanced melanoma and limited remaining standard options, the possibility of a meaningful and sometimes durable response may make the intensive process reasonable. For others, the expected burden of treatment, health risks, travel requirements or personal goals may lead to a different choice.

A balanced discussion should cover the chance of response, the possibility that treatment will not work, the need for surgery and hospital admission, side effects, recovery needs and alternative treatments. Patients may wish to involve family members, caregivers and supportive-care specialists in these conversations.

Ask your oncology team directly: what outcomes are realistic in my case, which complications matter most given my other health conditions, and what support will I have while I recover? For a decision this complex, a second specialist opinion is entirely reasonable too.

What Is the Success Rate of TIL Therapy for Treating Melanoma?

TIL therapy effectiveness in advanced melanoma is usually described using response rates: the proportion of treated people whose tumors shrink by a defined amount on scans. In a major study supporting approval of lifileucel, an FDA-approved TIL therapy for previously treated advanced melanoma, about one-third of participants had an objective response. Some responses were ongoing at the time results were reported.

These findings are encouraging for a group of patients with difficult-to-treat disease, but they are not a prediction of any one person’s outcome. Study participants had specific eligibility criteria, had received previous therapies and were treated in specialized settings. Response rates may also vary between studies, treatment approaches and patient populations.

Doctors also look beyond whether a tumor shrinks. They consider how long a response lasts, whether symptoms improve, possible treatment harms, quality of life and whether additional treatment is needed. Ongoing TIL therapy research aims to clarify which factors may help identify people most likely to benefit.

How Do You Feel Immediately After Immunotherapy?

How a person feels immediately after immunotherapy depends on the medicine and treatment setting. With TIL therapy, the cell infusion itself may be tolerated without major immediate symptoms, but patients are in hospital because the chemotherapy and interleukin-2 portions of treatment can cause substantial short-term effects.

During and shortly after this treatment, people may feel very tired, feverish, chilled, nauseated, weak or short of breath. Some develop low blood pressure, fluid retention or changes in blood counts and organ function. These effects are monitored by an experienced inpatient team, which can adjust supportive care according to the patient’s condition.

After standard outpatient checkpoint-inhibitor immunotherapy, some people feel well or have mild fatigue, aches, rash or flu-like symptoms. Others develop immune-related side effects days to months later. Any new or worsening symptom should be reported to the cancer team early, especially diarrhea, breathing changes, severe headache, yellowing of the skin or eyes, or marked weakness.

When to Seek Medical Care

Anyone with melanoma that has spread, cannot be fully removed by surgery, or has progressed after treatment should speak with a medical oncologist about the next steps. A referral to a center experienced in cellular therapy may be useful when TIL therapy is being considered, particularly because assessment and manufacturing require coordinated planning.

People currently receiving TIL therapy or recovering from it should seek urgent medical assessment for fever, chills, signs of infection, new breathing difficulty, chest pain, severe dizziness, confusion, significant bleeding, persistent vomiting or diarrhea, or inability to drink fluids. The treatment team should provide clear instructions about whom to contact outside office hours.

Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals can assess and treat eligible international patients with advanced melanoma, including coordinated planning for complex cancer therapies.

Frequently asked questions